BREAKING: Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months More detail, including interview with $CMPS CEO Kabir Nath, in our coverage... psychedelicalpha.com/news/compass-p…

One of the clearest signs that we are truly entering the age of psychedelic medicine: Compass Pathways - which my company, @atai_life, helped found and in which $ATAI still holds a strategic stake - announced this morning that it expects a potential FDA approval decision for its

#News: We’re thrilled to announce the successful completion of atai Life Sciences’ strategic combination with Beckley Psytech. Together, we are now AtaiBeckley, a global leader in transformative mental health therapies. Read the press release here: ir.ataibeckley.com/news-releases/…

Doing magic mushrooms this Sunday. Protocol + dose: 5 grams + frequency: 1x/mo for 3 mo + objective: exploring longevity effects Measurement + 249 independent biomarkers + 29 vials of blood + brain scans + urine, stool, saliva, fertility + multi-omics profiling (DNA,

#News for #investors and #media: Topline results from our Phase 2b open-label extension study of BPL-003 in treatment-resistant depression support the safety and efficacy of a second dose. Read more: ir.ataibeckley.com/news-releases/…

Bullish news for $ATAI | AtaiBeckley • Phase 2b OLE of BPL-003 shows 63 % response / 48 % remission in TRD 💥 • Fast recovery < 2 hrs, clean safety profile • Phase 3 → Q2 2026; FDA meeting in Q1 Psychedelic biotech is back — and $ATAI is leading the charge. 🧠📈

Ok, here is my trip report from 4.67 grams of magic mushrooms, 24.9 mg of psilocybin. The dose used in modern clinical trials. First, the experience was exhilarating. Positive in every way. I felt like a kid finding and exploring a new playground. My sensory perception was

I'm exploring magic mushrooms as a longevity therapy. Sunday was my first dose: 4.67 grams of dried Psilocybe cubensis (B+ strain), containing 24.98 mg of psilocybin. Here is an overview of the current scientific evidence: Longevity Psilocybin extended lifespan in mice and

#Q3 2025: a transformational quarter for AtaiBeckley! Highlights: ✅ BPL-003 received Breakthrough Therapy designation by the U.S. FDA for treatment-resistant depression ✅Reported positive Phase 2a and Phase 2b open-label extension data for BPL-003 Full update:

$ATAI Corporate Presentation November 2025 ir.ataibeckley.com/static-files/9… Updates: EMP-01: Oral R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) •Completed patient enrollment in the exploratory, randomized, double-blind,

AtaiBeckley just reported Q3 results - and I couldn’t be prouder of what our team has achieved. This year has been incredibly successful so far for $ATAI … and we’re only getting started. In Q3 alone: FDA granted Breakthrough Therapy designation for BPL-003 We reported

weekly protocol update: + completed tests post 5g 🍄 (25 mg psilocybin): + 114 blood biomarkers + 4x urine samples for hormone analysis + 6 kernel brain scans + 2 methylomic tests + 24/7 blood glucose monitoring + first brain scan results

First mushroom trip data is out: my brain activity. Dose: 5 g dried Psilocybe cubensis (B+ strain) Containing 24.9 mg psilocybin Psilocybin longevity experiment. What we see in the brain: + brain activity data mirror my subjective experience + strong decrease in my brain’s

436 depressed people. 9 clinical trials. 1 finding that changes everything: 𝗠𝗮𝗴𝗶𝗰 𝗺𝘂𝘀𝗵𝗿𝗼𝗼𝗺𝘀 𝘄𝗼𝗿𝗸 𝟯𝘅 𝗯𝗲𝘁𝘁𝗲𝗿 𝘁𝗵𝗮𝗻 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 𝗳𝗼𝗿 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻. The British Medical Journal just published what pharma

Hey guys, I am back. ❤️ I was blessed to meet the most forward thinking doctors from Stanford University and undergo a series of treatments to address trauma. I travelled to Tijuana Mexico and underwent Ibogaine treatment at AMBIO. Watch the Netflix documentary just

We were proud to sponsor this year’s Women in Government Leadership & Innovation Summit—an inspiring gathering of state legislators and policy leaders working to strengthen communities nationwide. Over two days in San Diego, attendees explored timely issues shaping public health

$MNMD New Jersey Lawmakers Approve Bill To Legalize Psilocybin Therapy MM